A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.
Recruiting · NCT07230483 · Interventional (participants receive a specific treatment) · Lead sponsor: Keymed Biosciences Co.Ltd
View the official record on ClinicalTrials.gov →Interventions studied
CM512
What this trial is about
This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).
- Subjects who have completed the week 18 evaluation in the parent study CM512-101102 or the End of Study(EOS) visit in the parent study CM512-100001.
Exclusion criteria
- Not enough washing-out period for previous therapy.
- Any other condition assessed by the investigator that makes participants unsuitable for participation in this study.
Where it is running
1 location listed.
- Peking University People's Hospital - Beijing, Beijing Municipality, China